OwlTail

Cover image of James M. Foran

James M. Foran

6 Podcast Episodes

Latest 9 Oct 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.

59mins

31 Mar 2021

Episode artwork

Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.

59mins

31 Mar 2021

Similar People

Episode artwork

Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.

59mins

31 Mar 2021

Episode artwork

Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

59mins

8 Apr 2019

Most Popular

Episode artwork

Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

59mins

8 Apr 2019

Episode artwork

Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

59mins

8 Apr 2019